资源描述
赛迪 赛 迪 顾 问股份 有限公 司 CCID Consulting Company Limited 2019 5 2019 ( ) ( ) 2019 5 37 13 35.1% 10 4 22 23 25 27 3 13 14 15 16 19 2 08 09 10 5 28 29 30 1 01 02 03 05 07 01 1 B 2 ( ) 3 Antibody Drug Conjugates, ADC Fc 2 2018 TOP10 6 2 Fc TOP10 199.36 1/2 1975 Milstein Kohler 1986 Ortholone OTK3 20 21 2018 TOP10 EvaluatePharma 2019 05 2019 05 3 1 Humria 199.36 2 Eliquis 98.72 3 Revlimid 96.85 4 Keytruda 71.71 5 Enbrel Fc 71.26 / 6 Herceptin 70.32 7 Avastin 68.98 8 Rituxan 68.01 9 Opdivo 67.35 10 Eylea Fc 65.73 / 74 79.5% Fc 12 12.9% ADC 5 2 5.4% 2.2% 57 71% 1986 2018 176 Food and Drug Administration FDA 93 FDA 46 FDA 2019 05 FDA FDA 2/2 4 1 1 2 5 1 1 2 3 3 3 2 1 3 5 1 6 4 3 7 10 7 10 12 FDA 2019 05 80% Fc 13% ADC 5% 2% 37% 34% 4% 4% 2% 2% 17%2011-2018 2011.07 40 700800 100 3040 10 2011.11 2012.01 / 2012.07 2013.01 2016.03 2016.08 10 2016.12 2016.12 2017.05 2019 05 1/2 5 2019 5 37 13 24 2018 2019 5 3 11 37.8% 2/2 - T CD3 1999 -8 2003 - 2005 131I 2006 131I 2006 2008 2011 - 2011 2014 - 2015 2018 2018 2019 6 NMPA 2019 05 1 1 1 2 1 2 1 1 2 1 1 2 2 1 1 3 1 1 1 9 2 NMPA 2019 05 1986 2018 FDA 93 - - - - -momab -ximab -zumab -mumab 1986 1994 1997 2004 % 0 60-70 90-95 100 % 50-80 1-57 0.1-8 0 ADC ADC Fc 2019 05 702 Fc 1 2019 05 9 1/3 / / Top10 EvaluatePharma 2019 05 165.2 68.8 68.9 74.1 37.4 184.3 71.4 68.1 59.4 57.4 199.4 70.3 70.0 68.0 67.4 2016 2017 2018 10 2/3 10000L 20000L 510g/L 2000L 5g/L 10 67 2020 90 30 2020 45 -55 CMO
展开阅读全文